NCT05173324

Phase 3Interventional

Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.

View on ClinicalTrials.gov ↗

Timeline

Start date: Feb 1, 2023
Primary completion: Jun 30, 2027
Completion date: Jun 30, 2027
First posted: Dec 29, 2021
Last posted: Aug 3, 2022
Enrollment: 8000
Arms / groups: 3 / —
Source: AACT · ctgov ingestion

Sponsors

International Agency for Research on CancerLead sponsor
Aga Khan UniversityCollaborator
Aga Khan UniversityStudy chair
Baylor UniversityCollaborator
Baylor UniversityStudy chair
Coptic Hope CenterCollaborator
Coptic Hope CenterStudy chair
Emory UniversityCollaborator
Emory UniversityStudy chair
International Agency for Research on CancerOverall official - principal investigator
International Agency for Research on CancerStudy chair
Government of SwazilandCollaborator
Sefako Makgatho Health Sciences UniversityCollaborator
Sefako Makgatho Health Sciences UniversityStudy chair
University of Kwa-Zulu NatalCollaborator
University of Kwa-Zulu NatalStudy chair
University of New MexicoCollaborator
University of New MexicoStudy chair
Stellenbosch UniversityCollaborator
Stellenbosch UniversityStudy chair
World Health OrganizationCollaborator
World Health OrganizationStudy chair
Aga Khan UniversityOfficial
International Agency for Research on CancerOfficial
Sefako Makgatho Health Sciences UniversityOfficial
Stellenbosch UniversityOfficial
Coptic Hope CenterOfficial
Emory UniversityOfficial
Baylor UniversityOfficial
University of New MexicoOfficial
World Health OrganizationOfficial
University of Kwa-Zulu NatalOfficial

Drugs studied

Indications studied

Papillomavirus Infections

CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.